Background: Hypertension is the chronic medical condition and it affected billions of
people worldwide. Natural medicines are the main alternatives to treatment for a majority of people
suffering from hypertension. Niazicin-A, Niazimin-A, and Niaziminin-B compounds from
Moringa oleifera ethanolic leave extract were reported to have potent antihypertensive activity.
Objective: These compounds were targeted with Angiotensin-converting enzyme [ACE] which is
one of the main regulatory enzymes of the renin-angiotensin system.
Methods: Protein-ligand docking of these compounds with [ACE] [both domain N and C] was
conceded out through Autodock vina and visualization was done by chimera. Pharmacokinetics
study of these compounds was predicted by ADME-Toxicity Prediction.
Results: Niazicin-A, Niazimin-A, and Niaziminin-B showed high binding affinity with ACE and
partially blocked the active sites of the enzyme. Niazicin-A, Niazimin-A and Niaziminin-B
showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol
respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively
with N-domain of ACE. The compounds showed better binding energy with angiotensinconverting
enzyme in comparison to Captopril -5.5kcal/mol and -5.6kcal/mol and Enalapril [standard]
-8.4kcal/mol and -7.5kcal/mol with C and N domain, respectively.
Conclusion: Computationally, the selected bioactive molecules have shown better binding energy
to known standard drugs which have been already known for inhibition of ACE and can further
act as a pharmacophore for in vitro and in vivo studies in the development of alternative medicine.